jueves, 30 de abril de 2026
Brief walking breaks help the body control sugar after carb-rich meals
https://www.news-medical.net/news/20260429/Brief-walking-breaks-help-the-body-control-sugar-after-carb-rich-meals.aspx
A small crossover study shows that interrupting long sitting periods with two-minute brisk walks may improve post-meal glucose control, while gluteal fat appears to play a stabilizing role after carbohydrate-rich meals.
New brain stimulation technique improves social communication in children with autism
https://www.news-medical.net/news/20260429/New-brain-stimulation-technique-improves-social-communication-in-children-with-autism.aspx
A new non-invasive brain stimulation technique known as accelerated continuous theta burst stimulation (a-cTBS) improves social communication at one month follow up and has a favorable safety profile in children with autism, finds a trial from China published by The BMJ today.
From killers to strategists: CAR T cells enter their multifunctional era
https://www.news-medical.net/news/20260430/From-killers-to-strategists-CAR-T-cells-enter-their-multifunctional-era.aspx
A sweeping trial landscape review shows how CAR T therapy is moving beyond one-target designs toward multifunctional “living drugs” designed to improve safety, overcome tumor escape, and tackle harder-to-treat cancers.
Rare Sugars vs. Regular Sugar: Which is Better for Glucose Control?
https://www.news-medical.net/health/Rare-Sugars-vs-Regular-Sugar-Which-is-Better-for-Glucose-Control.aspx
Rare sugars may offer a smarter way to sweeten foods, but their real promise depends on dose, sugar type, and stronger long-term human evidence.
The rising prevalence of obesity and type 2 diabetes throughout the world is largely attributed to the excessive intake of refined carbohydrates and added sugars. Common sugars such as sucrose, fructose, and high-fructose corn syrup have been specifically implicated in adverse cardiometabolic outcomes. In response to this growing public health burden, researchers and food manufacturers are increasingly exploring alternative sweeteners, such as rare sugars, that may offer similar sweetness with a lower metabolic burden.3
HPV infections continue after age 27, so who is still at risk?
https://www.news-medical.net/news/20260430/HPV-infections-continue-after-age-27-so-who-is-still-at-risk.aspx
New real-world data reveal that HPV risk doesn’t end in early adulthood, offering critical insights into lifelong infection patterns and what they mean for vaccination decisions in older women.
From a moment, to momentum: Why Undiagnosed Day 2026 is shaping what happens next 29 April 2026 By Helene Cederroth, president and founder, The Wilhelm Foundation
https://rarerevolutionmagazine.com/from-a-moment-to-momentum-why-undiagnosed-day-2026-is-shaping-what-happens-next/
As we recognise Undiagnosed Day 2026, Helene Cederroth, president and founder of Wilhelm Foundation, discusses the progress that has been made in the past year for people living with undiagnosed diseases, and how the mission remains: to ensure no one is left behind
The one-pot solution to snakebite’s century-old problem
The one-pot solution to snakebite’s century-old problem
A single-batch bacterial system for producing nanobody cocktails could make snakebite treatment far more affordable and scalable.
https://www.drugdiscoverynews.com/the-one-pot-solution-to-snakebite-s-century-old-problem-17145
Coming from Scandinavia, Anne Ljungars admits she had never given much thought to snakebite envenoming. “Is that even a problem?” she told DDN, recalling her initial reaction when she first encountered the field. In Sweden or Denmark, snake envenoming barely registers as a public health concern. Globally, however, it is a very different story.
An Overview of Systemic Mastocytosis by Madaline Spencer| Published on: Apr 30, 2026
An Overview of Systemic Mastocytosis
by Madaline Spencer| Published on: Apr 30, 2026
Dareen D. Siri, MD, FAAAAI, FACAAI is a board-certified allergist and immunologist practicing at Midwest Allergy Sinus Asthma, based in central Illinois. She talked with CheckRare about a unique, rare disorder called systemic mastocytosis.
https://checkrare.com/an-overview-of-systemic-mastocytosis/
Proteomics-driven insights for pharmaceutical development Publication highlights April 2026
Proteomics-driven insights for pharmaceutical development
Publication highlights April 2026
Escalating costs and increasing demands from regulatory authorities for a more precision medicine-based approach to drug development are substantial challenges for the pharmaceutical industry. Olink’s PEA technology is increasingly used to identify new drug targets and analyze samples from clinical trials to stratify patient populations, predict responses, and provide insights into the biology of disease and drug modes of action. Here we highlight some recent outstanding studies that illustrate the key role of protein biomarker research in the discovery and development of new therapies.
https://olink.com/blog/proteomics-driven-insights-for-pharmaceutical-development?utm_campaign=26-01-global-core-genomics-virtual-journal-club&utm_medium=email&_hsenc=p2ANqtz-987lCEnxWVyVHTyXD3YOu4QWS9GrHGff0H8QV_4FDYDPlWsNoryP09Cfzz-gEmpKqjjrI2X87PaP3qnmzn9wSH29QsaQ&_hsmi=416418473&utm_content=cta-1&utm_source=olink
miércoles, 29 de abril de 2026
FDA Releases Results from Largest-Ever Testing of Infant Formula in the U.S. Agency to Continue Rigorous Oversight and Additional Testing
https://www.fda.gov/news-events/press-announcements/fda-releases-results-largest-ever-testing-infant-formula-us?utm_medium=email&utm_source=govdelivery
The U.S. Food and Drug Administration today announced results from the largest and most rigorous examination ever conducted focused on chemical contaminants in infant formula available on the U.S. market. While breast milk is widely considered the gold standard and optimal source of nutrition for infants whenever possible, millions of parents depend on formula.
https://www.fda.gov/food/infant-formula-homepage/fdas-infant-formula-product-testing-results?utm_medium=email&utm_source=govdelivery
“We tested more infant formula than ever before, and the results are clear: most products meet a high safety standard—but even small exposures matter for newborns,” said Health and Human Services Secretary Robert F. Kennedy, Jr. “We will hold manufacturers accountable, and give parents honest, transparent data they can trust. Protecting our children’s health is nonnegotiable.”
“You can judge a society by how it treats its most vulnerable members. That’s why we’re doing everything in our power to make sure our babies and infants have safe, high quality formula options that are backed by a resilient supply chain,” said FDA Commissioner Marty Makary, M.D., M.P.H. “The results of this study are encouraging. We will continue to advance formula innovation and safety for the millions of families who depend on it.”
Across the products tested, an overwhelming majority of samples had undetectable or very low levels of contaminants, affirming that the U.S. infant formula supply is safe. The FDA tested more than 300 infant formula samples representative of products sold at retail across the U.S.—generating more than 120,000 data points—for lead, mercury, cadmium, arsenic, pesticides (including glyphosate and glufosinate), per- and polyfluoroalkyl substances (PFAS), and phthalates. The samples, which included powders, ready-to-feed liquids, and concentrated liquids, were rigorously tested and analyzed in FDA laboratories.
While overall levels of contaminants in the infant formula samples tested were low, the FDA is following up with additional testing as part of the agency’s ongoing robust monitoring and oversight efforts and will take additional action where appropriate. This includes conducting further testing, including for additional contaminants, continuing to engage with manufacturers on measures to reduce the levels of contaminants to as low as possible, and working to establish action levels for contaminants in infant formula.
“As a father, I understand how important it is for parents to trust the safety of the food they give their children. At the FDA, ensuring the health of America's next generation is vital,” said Kyle Diamantas, J.D., Deputy Commissioner for Deputy Commissioner for Food. “Through Operation Stork Speed and our Closer to Zero initiative, this testing—the first of its kind—reinforces that infant formula in the U.S. is a safe option for parents and caregivers who rely on it. We will continue working to drive contaminants to as low as possible through rigorous oversight.”
Small amounts of contaminants may be present in foods—including infant formula and breast milk—because they occur naturally or enter the environment through human activities in the areas where ingredients are grown or produced.
This testing was conducted as part of Operation Stork Speed, the FDA’s Closer to Zero initiative, and the FDA’s routine food surveillance work to help ensure safe, reliable, and nutritious infant formula for families across the U.S.
The FDA will continue to test infant formula as part of Operation Stork Speed and ongoing surveillance of foods, including testing infant formula products that have entered the U.S. market since this initial survey began and conducting additional compliance sampling. Consistent with FDA’s commitment to transparency, the agency will share results from follow-up surveys.
Secretary Kennedy will host chief executives from leading infant formula companies in May for a roundtable discussion focused on modernizing FDA’s infant formula oversight and continued implementation of Operation Stork Speed, which includes aspects of nutrition, chemical, and microbiological food safety.
Neurologic Side Effects Rare but Often Severe With Immune Checkpoint Inhibitors Liam Davenport April 29, 2026
https://www.medscape.com/viewarticle/neurologic-side-effects-rare-often-severe-immune-checkpoint-2026a1000dok
Although neurologic adverse events are uncommon with immune checkpoint inhibitor (ICI) therapy, they may take months to occur, are often severe, and commonly result in treatment discontinuation, according to a retrospective analysis.
https://www.medscape.com/c25/p14/european-association-dermato-oncology-eado-congress-2026-2026a1000ale
Surveillance Strategies for Hepatocellular Carcinoma: New Update Diana Swift April 29, 2026
https://www.medscape.com/viewarticle/surveillance-strategies-hepatocellular-carcinoma-new-update-2026a1000dov
Advancements in surgical, locoregional, and systemic therapies have improved outcomes for early hepatocellular carcinoma (HCC), but most cases are diagnosed at later stages owing to the limitations and underuse of current surveillance modalities.
Re-endangerment The Lancet Planetary Health ++... ++
Re-endangerment
The Lancet Planetary Health
https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00036-7/fulltext?dgcid=raven_jbs_etoc_email
Mar 2026
Volume 10Number 3
https://www.thelancet.com/journals/lanplh/issue/vol10no3/PIIS2542-5196(26)X2003-4
Association between Great Salt Lake desiccation, air quality, and major depressive episodes: an ecological study
Maheshwari Neelam, PhDa Send email to maheshwari.neelam@nasa.gov ∙ Kamaldeep Bhui, MDb ∙ Trent Cowan, MScc ∙ Brian Freitag, PhD
https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(25)00283-9/fulltext?dgcid=raven_jbs_etoc_feature_lanplh
Dichlorodiphenyltrichloroethane and dichlorodiphenyldichloroethylene exposure, cognition, and cortical thickness at middle age in US Latinas (the CHAMACOS Maternal Cognition Study): a prospective cohort study
Prof Brenda Eskenazi, PhDa,b Send email to eskenazi@berkeley.edu ∙ Yishu Chao, BAc ∙ Lucia Calderon, MPHd ∙ Stephen Rauch, MPHa,b ∙ Katherine Kogut, MPHa,b ∙ Marcella Warner, PhDa,b ∙ et al.
https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00014-8/fulltext?dgcid=raven_jbs_etoc_feature_lanplh
It’s time to seize the rare bipartisan opening to address microplastics A surprising federal announcement offers a rare opportunity on a serious health and fertility challenge
https://www.statnews.com/2026/04/28/microplastics-nanoplastics-health-epa-trump-arpa-h/
By Tim Ryan and Justin ZornApril 28, 2026
Ryan is a former 10-term Democratic member of the U.S. Congress from Ohio. Zorn is a senior adviser at the Center for Economic and Policy Research.
Google clinical director says AI can be a ‘bridge’ for people having a mental health crisis Cutting users off ‘could do more harm than good,’ Megan Jones Bell told STAT
https://www.statnews.com/2026/04/28/google-gemini-ai-mental-health-safety-interview-clinical-director-megan-jones-bell/
By Mario AguilarApril 28, 2026
Health Tech Correspondent
Why do discussions about ‘brain health’ ignore mental illness? The divide between mental illness and neurological disorders is a scientific and strategic error
https://www.statnews.com/2026/04/28/brain-health-mental-illness-neurodegenerative-disorders-connection/
By Husseini K. Manji, Eric J. Nestler, and Patrick J. KennedyApril 28, 2026
Manji is a professor at Oxford University, a professor (adjunct) at Yale University, and co-chair of the U.K. government Mental Health Goals program. Nestler is the Anne and Joel Ehrenkranz dean of the Icahn School of Medicine at Mount Sinai, chief scientific officer and executive vice president of the Mount Sinai Health System, and a professor of neuroscience and psychiatry. Patrick Kennedy is a former U.S. congressman.
Quality of Life in Patients With Pulmonary Arterial Hypertension by Madaline Spencer| Published on: Apr 27, 2026
https://checkrare.com/quality-of-life-in-patients-with-pulmonary-arterial-hypertension/
A study recently published in Health and Quality of Life Outcomes analyzed quality of life in patients with pulmonary arterial hypertension (PAH).
Daybue (Trofinetide) Stix: New Formulation of Treatment for Rett Syndrome by Madaline Spencer| Published on: Apr 28, 2026
Daybue (Trofinetide) Stix: New Formulation of Treatment for Rett Syndrome
by Madaline Spencer| Published on: Apr 28, 2026
Arthur Beisang, MD, Department of Pediatrics at Gillette Children’s Specialty Healthcare in Saint Paul, Minnesota, discusses Daybue (trofinetide) Stix, a new formulation of the treatment for Rett syndrome.
https://checkrare.com/daybue-trofinetide-stix-new-formulation-of-treatment-for-rett-syndrome/
Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated With Velaglucerase Alfa by Madaline Spencer| Published on: Apr 29, 2026
https://checkrare.com/bone-mineral-density-in-patients-with-type-1-gaucher-disease-treated-with-velaglucerase-alfa/
A study published in the Journal of Clinical Medicine evaluated the improvement of bone mineral density in patients with type 1 Gaucher disease (GD1) treated with velaglucerase alfa.
Accelerated Approval Granted to Gene Therapy for Rare Genetic Hearing Loss by Madaline Spencer| Published on: Apr 29, 2026
Accelerated Approval Granted to Gene Therapy for Rare Genetic Hearing Loss
by Madaline Spencer| Published on: Apr 29, 2026
The US Food and Drug Administration (FDA) has granted accelerated approval for Otarmeni (lunsotogene parvec) for the treatment of patients with otoferlin (OTOF)-related hearing loss. The indication includes pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear.
https://checkrare.com/accelerated-approval-granted-to-gene-therapy-for-rare-genetic-hearing-loss/
Biomarkers and Beyond: Integrating AI in Rare Disease Management by CheckRare Staff| Updated on: Apr 18, 2026
Stacey Kallish, MD, Clinical Geneticist at Penn Medicine in Philadelphia, is helping to lead a new wave of innovation at the intersection of artificial intelligence (AI) and rare disease care. With a clinical focus on lysosomal storage diseases (LSDs)—including Fabry disease, Gaucher disease, and Pompe disease—Dr. Kallish is exploring how emerging technologies can improve diagnosis, risk prediction, and long-term management for patients with complex genetic conditions.
https://checkrare.com/biomarkers-and-beyond-integrating-ai-in-rare-disease-management/
FDA Releases FY25 Sampling Results on Economically Motivated Adulteration in Honey
https://www.fda.gov/food/hfp-constituent-updates/fda-releases-fy25-sampling-results-economically-motivated-adulteration-honey?utm_medium=email&_hsenc=p2ANqtz-8jvSYPL9bouVvar0Tp-3UrqfgtO-WjTzMDMaFb5u-4O8xF3M3n7sgrDqpBrQHlBehTp1ltfwc935DvUC7YI4NoMmwwIw&_hsmi=416156928&utm_source=govdelivery
FDA Sampling Results Reinforce Focus on Economically Motivated Adulteration
FDA has released FY2025 sampling results highlighting its ongoing focus on economically motivated adulteration (EMA), where products are altered or diluted to reduce costs without proper disclosure. While the testing focused on honey, the broader priority is detecting ingredient substitution and fraud across food imports. For importers and exporters, this reinforces the need for strong supplier verification, product testing, and documentation, as adulteration risks can trigger import alerts, refusals, and increased regulatory scrutiny.
Campaigning to improve sepsis recognition and outcomes The Lancet Respiratory Medicine ++... ++
Campaigning to improve sepsis recognition and outcomes
The Lancet Respiratory Medicine
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00121-9/fulltext?dgcid=raven_jbs_etoc_email
May 2026
Volume 14Number 5p375-462, e31-e32
https://www.thelancet.com/journals/lanres/issue/vol14no5/PIIS2213-2600(26)X2004-5
Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial
Prof Malcolm G Semple, PhDa,b Send email to m.g.semple@liverpool.ac.uk ∙ Chloe Donohue, BScc ∙ Laura Price, BScc ∙ Rachael Cooper, MScc ∙ Carly Vaughan, BScc ∙ Tracy Moittc ∙ et al.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00008-1/fulltext?dgcid=raven_jbs_etoc_feature_lanres
Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial
Prof Javier A Neyra, MDa ∙ Prof Matthieu Legrand, MDb Send email to matthieu.legrand@ucsf.edu ∙ Prof Mark A Tidswell, MDd ∙ Prof Ali Al-Khafaji, MDe ∙ Claude Galphin, MDf ∙ Ronald Rains, MDg ∙ et al.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00047-0/fulltext?dgcid=raven_jbs_etoc_feature_lanres
Boosting the immune response to brain cancer
Boosting the immune response to brain cancer
At a Glance
Stopping certain immune cells from using fructose for fuel enhanced the immune response to brain cancer in mice.
The results point to a way to make immunotherapies more effective for a form of cancer that is often resistant to their effects.
https://www.nih.gov/news-events/nih-research-matters/boosting-immune-response-brain-cancer
Weakened gut-brain connection may contribute to memory loss
Weakened gut-brain connection may contribute to memory loss
At a Glance
Researchers found that changes to gut bacteria in aging mice hindered communication from the gut to the brain and led to worse performance on memory tasks.
If these results hold true in humans, they could inspire treatments to prevent, reduce, or even reverse age-related cognitive decline.
https://www.nih.gov/news-events/nih-research-matters/weakened-gut-brain-connection-may-contribute-memory-loss
AI tool predicts patients at risk of intimate partner violence
AI tool predicts patients at risk of intimate partner violence
At a Glance
A new artificial intelligence tool can predict patients who are likely to experience intimate partner violence years before they seek help.
The tool may eventually help health care providers identify patients at risk of intimate partner violence and provide early interventions.
https://www.nih.gov/news-events/nih-research-matters/ai-tool-predicts-patients-risk-intimate-partner-violence
martes, 28 de abril de 2026
2026 Family Heart Global Summit October 2 & 3, 2026 | San Diego, CA
https://www.familyheartsummit.org/event/743c2275-3b7b-442d-adcc-c5d8b9040207/summary
Announcing Keynote Speaker Valentín Fuster, MD, PhD
The Family Heart Foundation cordially invites you to join us for our 12th annual Family Heart Global Summit® on October 2 & 3, 2026 in San Diego, California.
We are honored to feature Dr. Valentín Fuster as a keynote speaker at the 2026 Family Heart Global Summit. Widely regarded as one of the most influential leaders in cardiovascular medicine, Dr. Fuster has played a central role in shaping how heart disease is understood, prevented, and managed worldwide.
The Summit convenes leaders across research, clinical care, industry, and the patient community to advance the prevention of cardiovascular disease, with a focus on LDL cholesterol, familial hypercholesterolemia, and high lipoprotein(a).
Join us for a dynamic program bringing together experts across disciplines to shape the future of cardiovascular health.
Small Steps and Giant Leaps: Charting a Course for Cardiovascular Disease Prevention
Combination therapy doubles one-year survival in pancreatic cancer trial
Combination therapy doubles one-year survival in pancreatic cancer trial
Findings from the randomized trial suggest that modulating the tumour microenvironment alongside chemotherapy may offer a new strategy for improving outcomes in pancreatic cancer
https://www.drugdiscoverynews.com/combination-therapy-doubles-one-year-survival-in-pancreatic-cancer-trial-17121?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9RiEgzqG9BeKuO8WgnmSKpSqzPzTpSI9AbY17AuDEDKdDSUrIjlVCO8YgrLjYA3YPQMpNYgKswuehIRq3e_fQVVk1tNA&_hsmi=416164333&utm_content=416164333&utm_source=hs_email
A drug developed at Northwestern University has shown a promising survival advantage in patients with metastatic pancreatic cancer, a disease that remains among the deadliest solid tumours and is projected to become the second leading cause of cancer-related deaths in the US within the next decade.
How fecal microbiota transplantation could transform cancer immunotherapy
How fecal microbiota transplantation could transform cancer immunotherapy
Emerging clinical trials suggest that the gut microbiome plays a decisive role in how patients respond to immunotherapy.
https://www.drugdiscoverynews.com/how-fecal-microbiota-transplantation-could-transform-cancer-immunotherapy-17017?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_hvwvtjeaeQ8I5BJ6BizhL7blcUinEmyYuCIES5SxcSnhKdq_yUK-WNzR4ESQrFVU2dgWmmh5slJMDVTPWOomx5RSqOQ&_hsmi=416164333&utm_content=416164333&utm_source=hs_email
Over the past decade, scientists have learned that cancer is not driven by tumor cells alone. Disruptions in the gut microbiome have been linked to cancer development and progression through effects on genomic stability, immune evasion, and the tumor microenvironment.
Dissecting the Bladder Tumour Microenvironment with MB49 21st January 2026
Dissecting the Bladder Tumour Microenvironment with MB49
21st January 2026
Cell lines
Introduction
Immunotherapy has started to transform bladder cancer treatment, but durable responses remain the exception rather than the rule. Understanding why requires models that capture the tumour microenvironment, not just tumour growth. This blog explores how the MB49 syngeneic bladder cancer model – across subcutaneous, orthotopic, MB49-luc, and metastatic formats – dissects myeloid-dominated “cold” TMEs, neutrophil-driven immune escape, BCG response, and PD-L1-dependent checkpoint timing.
https://cancertools.org/dissecting-bladder-tumour-microenvironment-with-mb49/?utm_term=3rd%20party%20-%20DDN%20-%20MB49%20blog&utm_campaign=43046019-Bladdercancer_DM_BrandAwareness_ALL_2026&utm_medium=3rd%20party%20-%20DDN%20-%20MB49%20blog&_hsenc=p2ANqtz--FJN0fijn2qnnW93DyMevFIKuE7zjKxplXeN_tIUh52Ae7k9kLYqHh46kHvpVUZFt95kA8wDpij8WmRUYr3TubgDVI_g&_hsmi=416164333&utm_content=3rd%20party%20-%20DDN%20-%20MB49%20blog&utm_source=3rd%20party%20-%20DDN%20-%20MB49%20blog
Gut microbes may flag Parkinson’s risk years before symptoms appear
Gut microbes may flag Parkinson’s risk years before symptoms appear
Researchers have identified a distinctive gut microbiome pattern linked to Parkinson’s disease that appears in both diagnosed patients and a subset of symptom-free individuals who may already be on a disease trajectory.
https://www.drugdiscoverynews.com/gut-microbes-may-flag-parkinson-s-risk-years-before-symptoms-appear-17139
Parkinson’s disease (PD) is usually diagnosed only after movement problems appear, when more than half of dopamine-producing neurons in the brain have already been lost. By that point, the biological processes driving degeneration have likely been underway for years. A new international study, published in Nature Medicine, suggests those early changes may be detectable not in the brain, but in the gut.
How an enzyme helps lung cancer survive radiation, and how to stop it
How an enzyme helps lung cancer survive radiation, and how to stop it
Researchers identified a mitochondrial enzyme that shields lung cancer cells from a radiation-induced cell death process — and then found that an existing arthritis drug can disable that shield.
https://www.drugdiscoverynews.com/how-an-enzyme-helps-lung-cancer-survive-radiation-and-how-to-stop-it-17144
Radiation therapy is among the most widely used treatments for lung cancer, but its effectiveness is frequently undermined by a familiar problem: Tumors that initially respond to treatment develop resistance and begin growing again. How exactly that resistance forms has remained incompletely understood, and the mechanisms that allow cancer cells to survive radiation-induced damage continue to be an active area of investigation.
War Related Illness and Injury Study Center’s (WRIISC) 25th Anniversary: Advancing Exposure-Related Care and Research Together with Veterans DATE: Thursday, May 7, 2026 TIME: 1:00 p.m. - 2:00 p.m. ET LOCATION: VIRTUALLY through WebEx
https://content.govdelivery.com/attachments/USVHA/2026/04/27/file_attachments/3630943/Advancing%20Exposure-Related%20Care%20WRIISC%E2%80%99s%2025th%20Anniversary.pdf
Join us to learn about the War Related Illness and Injury Study Center (WRIISC) and its contributions to advancing care for Veterans with exposure concerns. This special event honoring WRIISC’s 25th Anniversary will share the major research and clinical milestones achieved over the past 25 years. This webinar takes place on Thursday, May 7th, at 1:00 p.m. ET. You can attend through your personal computer, smart phone, or tablet.
To learn more about this class and sign up, see the attached class flyer.
War in the Middle East: collateral damage The Lancet Oncology ++ + +...
Estimating the impact of scaling up workforce personnel on global cancer mortality from 2030 to 2050: a simulation-based analysis of 17 cancers and 18 personnel types
Zachary J Ward, PhDa,b,c Send email to zward@hsph.harvard.edu ∙ Fabio Ynoe Moraes, MDe,f ∙ Prof Andrew M Scott, MDg,h,i,j ∙ Fernanda M Favoritok ∙ Prof Wil Ngwa, PhDl ∙ Prof Timothy R Rebbeck, PhDd,m ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00062-8/abstract?dgcid=raven_jbs_etoc_feature_lanonc
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium
Prof Joachim Widder, MD PhDa Send email to joachim.widder@muv.ac.at ∙ Guus M Bol, MD PhDb,c ∙ Inga-Malin Simek, MDa ∙ Felix Ehret, MDd,e ∙ Hoda Abdel-Aty, FRCR MD[Res]f ∙ Selma Basicg ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00075-6/abstract?dgcid=raven_jbs_etoc_feature_lanonc
War in the Middle East: collateral damage
The Lancet Oncology
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00187-7/fulltext?dgcid=raven_jbs_etoc_email
May 2026
Volume 27Number 5p527-648, e232-e270
https://www.thelancet.com/journals/lanonc/issue/vol27no5/PIIS1470-2045(26)X2004-6
Rewriting the Genetic Code: Designing Biologics with Noncanonical Amino Acids avatar David Alvaro, Ph.D. Editor in Chief April Stanley, MS MBA Senior Scientific Research Director and M&A Advisor Nice Insight
Rewriting the Genetic Code: Designing Biologics with Noncanonical Amino Acids
David Alvaro, Ph.D.
Editor in Chief
April Stanley, MS MBA
Senior Scientific Research Director and M&A Advisor
Nice Insight
https://www.pharmasalmanac.com/articles/rewriting-the-genetic-code-designing-biologics-with-noncanonical-amino-acids
Advances in genetic code expansion are enabling the incorporation of noncanonical amino acids into proteins, expanding the chemical capabilities of biologics and opening new possibilities for designing therapeutic proteins with precisely engineered functions.
lunes, 27 de abril de 2026
What’s the true risk for eating disorders with GLP-1s? The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning Rounds
https://www.statnews.com/2026/04/27/health-news-true-risk-of-eating-disorders-and-wegovy-ozempic/
By Theresa GaffneyApril 27, 2026
Morning Rounds Writer and Reporter
Zap in a cap: How one neurotech startup is using a hat to treat depression FDA approved Motif Neurotech’s application to test its brain implant for treatment-resistant depression in a feasibility trial
https://www.statnews.com/2026/04/27/motif-neurotech-gets-fda-nod-brain-implant-depression/
By O. Rose BroderickApril 27, 2026
Disability in Health Care Reporting Fellow
Veradermics’ hair loss drug succeeds in late-stage trial The company is a major player in the field, which has seen a surge of investor enthusiasm
https://www.statnews.com/2026/04/27/veradermics-hair-loss-drug-succeeds-late-stage-trial/
By Allison DeAngelisApril 27, 2026
Biotech Startups and Venture Capital Reporter
Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study Drug could become new treatment option, and a blockbuster, if data hold up in late-stage trials
https://www.statnews.com/2026/04/27/ourka-psoriasis-inectable-treatment-study/
By Adam FeuersteinApril 27, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial Data set up approval of what would be second gene editing medicine
https://www.statnews.com/2026/04/27/intellia-therapeutics-phase-3-trial-hereditary-angioedema-crispr-treatment/
By Jason MastApril 27, 2026
General Assignment Reporter
How Pets Improve Mental Health and Reduce Stress
https://www.news-medical.net/health/How-Pets-Improve-Mental-Health-and-Reduce-Stress.aspx
From reducing stress and anxiety to fostering social connection and comfort, animal-assisted therapy demonstrates how carefully guided human-animal interaction can complement modern care.
Animal-assisted therapy (AAT) is gaining recognition as a complementary clinical approach that uses structured interactions with trained animals to support emotional, cognitive, and physical health.
Did life-saving HIV drugs unintentionally fuel a syphilis comeback?
A life-saving HIV breakthrough reshaped survival. But did it also reshape sexual behavior and spark an unexpected public health challenge?
https://www.news-medical.net/news/20260427/Did-life-saving-HIV-drugs-unintentionally-fuel-a-syphilis-comeback.aspx
A recent study published in Health Economics reveals that the breakthrough discovery of antiretroviral therapy for HIV might have unintentionally triggered the resurgence of syphilis, a sexually transmitted infection, in the United States.
Symptom-based approach treats opioid withdrawal in newborns with minimal drug exposure
Symptom-based approach treats opioid withdrawal in newborns with minimal drug exposure
https://www.nih.gov/news-events/news-releases/symptom-based-approach-treats-opioid-withdrawal-newborns-minimal-drug-exposure
NIH-funded clinical trial shows that the new approach could also decrease time in the hospital.
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institutes of Health
SYMPTOM-BASED APPROACH TREATS OPIOID WITHDRAWAL IN NEWBORNS WITH MINIMAL DRUG EXPOSURE
NIH-funded clinical trial shows that the new approach could also decrease time in the hospital
A National Institutes of Health (NIH)-funded clinical study shows that a symptom-based treatment for babies with neonatal opioid withdrawal syndrome (NOWS) , Devlin and her colleagues compared a symptom-based approach to a traditional scheduled dosing approach.
In this study, 383 infants with moderate to severe NOWS who were cared for with the family-centered Eat, Sleep, Console (ESC) approach were split into two groups.
One group of 194 infants received scheduled opioids which were tapered after signs of withdrawal were well controlled. The other group of 189 infants received doses of opioid medication when their signs of withdrawal reached a prespecified threshold and only received additional doses if their withdrawal severity once again reached the threshold for treatment. Established guardrails prevented undertreatment for infants whose withdrawal did not improve with symptom-based opioid dosing.
The researchers recorded the length of time until each newborn was ready to go home. They found that babies receiving the symptom-based dosing were ready to go home two days earlier than babies receiving the scheduled dosing. The researchers also found that the symptom-based group stopped medication sooner.
The researchers did not find that symptom-based dosing conferred the same benefits to infants with NOWS who were initially cared for through the traditional, healthcare provider-centric Finnegan approach instead of ESC.
Since the trial, several hospitals involved in the study have adopted the symptom-based strategy - and the authors believe their results may inform broader adoption.
"The opioid epidemic is still a huge problem, but this is a simple and powerful way we can get these babies ready to go home faster. This is best for their family and for their own development," said study co-author Augusto Schmidt, M.D., Ph.D., a program officer at NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
The trial is part of the Helping to End Addiction Long-term(r) Initiative, or NIH HEAL Initiative (r) and was supported by NICHD grants U24HD107621, UG1HD107580, UG1HD107616, UG1HD107627, UG1HD107628, UG1HD107631, UG1HD107649, UG1HD107650, and UG1HD107653.
NIH HEAL Initiative and Helping to End Addiction Long-term are registered service marks of the U.S. Department of Health and Human Services.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
---
REFERENCES: Lori A. Devlin et al. Symptom-Based Dosing for Neonatal Opioid Withdrawal: Outcomes from the OPTimize NOW Study. The Journal of the American Medical Association. 2026. DOI: 10.1001/jama.2026.5782
###
This NIH News Release is available online at:
Advancing Real-Time CGM Use for Improved Patient Outcomes
Advancing Real-Time CGM Use for Improved Patient Outcomes
Advance your expertise in real-time CGM with a new, expert-led online Learning Center designed specifically for clinicians. Developed by Dr Viral Shah and leading authorities in diabetes care, this free resource hub delivers accredited continuing education, the latest clinical evidence, and practical tools to help you optimize patient outcomes.
https://www.medscape.org/advances/advancing-real-time-cgm-use-improved-patient-outcomes-2026a10005mw?src=ban_driv_260312_mscpedu_448737.01_ace
Doctors Aren't Dietitians: The Flaws in the New HHS Nutrition Education Initiative Giamila Fantuzzi, PhD; Kirsten A. Straughan, MS, RDN, LDN, CSSD April 10, 2026 ++++++ +++
https://www.medscape.com/viewarticle/doctors-arent-dietitians-flaws-new-hhs-nutrition-education-2026a1000am1?ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
“This isn't about turning doctors into dietitians,” said Bobby Mukkamala, MD, president of the American Medical Association, during a discussion of the federal effort to increase the time medical students spend on nutrition education.
In 2023, a scientifically structured process identified 36 competencies to enhance nutrition knowledge among medical students and physician trainees. Then, in early March 2026, the Department of Health and Human Services released a new list of 71 competencies.
Docs Train Teachers to Treat Anaphylactic Shock
https://www.medscape.com/viewarticle/when-school-nurse-miles-away-teachers-treat-anaphylactic-2026a1000ctc?ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
Are Atopic Dermatitis Caregivers Over-Restricting Diets?
https://www.medscape.com/viewarticle/survey-highlights-dietary-concerns-among-caregivers-children-2026a10008uw?ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
Precision Medicine for Rare Allergies
https://www.medscape.com/viewarticle/precision-medicine-rare-allergies-2026a1000bv0?ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
Autoimmune Disease in Parent Tied to Kid’s Allergy Risk
https://www.medscape.com/viewarticle/autoimmune-disease-parent-tied-allergy-risk-child-2026a1000amv?ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
GLP-1s May Reduce Asthma Exacerbations in Obese Adults
https://www.medscape.com/viewarticle/glp-1s-may-reduce-asthma-exacerbations-adults-overweight-and-2026a1000cme?ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
Markers May Predict Response to Cockroach Allergen
https://www.medscape.com/viewarticle/markers-may-predict-response-cockroach-allergen-challenge-2026a10009ly?ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
Allergy Myths Abound on Social Media: Debunk With Care
Whitney McKnight
https://www.medscape.com/viewarticle/allergy-myths-abound-social-media-debunk-care-2026a1000bw0?ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
Does a "tolerant" IgG result safely rule out a food allergy? (Ask Medscape AI)
https://www.medscape.com/ai-search?query=Does%20a%20%22tolerant%22%20IgG%20result%20safely%20rule%20out%20a%20food%20allergy%3F&ecd=mkm_ret_260427_mscpmrk_allergy_top-content_mai_etid8292806&uac=148436CN&impID=8292806
April 16, 2026
domingo, 26 de abril de 2026
European Association of Dermato-Oncology (EADO) Congress 2026
https://www.medscape.com/c25/p14/european-association-dermato-oncology-eado-congress-2026-2026a1000ale
11th World Congress of Melanoma (WCM) and 21st EADO Congress 2025
https://www.medscape.com/viewcollection/37751
Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents
Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents
Christian E. Edvardssona ∙ Xinming Zhangb,c ∙ Thaynnam A. Emousa,d ∙ Louise Adermarka,e ∙ Sarah Witleya ∙ Mia Ericsone ∙ et al.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00101-5/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz--Zh0sGt0Ic-AuRNyTeKt-OauAOMjeBSaZg3W-ySCJMLHUFUiPUWdv7oC4Yod9rFc8JoUTIILs3P7dM40lCpxkBZ_3AMg&_hsmi=415197735&utm_content=414889854&utm_source=hs_email
The landscape of gene mutations in a cohort of 3353 Han Chinese children with nonsyndromic hearing loss + +...
The landscape of gene mutations in a cohort of 3353 Han Chinese children with nonsyndromic hearing loss
Yun Xiaoa,d,e ∙ Lei Chena,e ∙ Yuechen Hana,d ∙ Jianfen Luoa,b ∙ Mingming Wanga ∙ Yu Aia,c ∙ et al.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00093-9/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz--dLkfRRyodBvUb15sfAGPq7YPQv2W5NtLEbK045c3YHKGtrA4WKMbwgNrDV_B5raxR8vGRoC2p0AB0Of5JuvKKJWWlOw&_hsmi=415197735&utm_content=414889854&utm_source=hs_email
Apr 2026
Volume 126
https://www.thelancet.com/journals/ebiom/issue/vol126nonull/PIIS2352-3964(26)X2002-3
Editorial Treating alcohol use disorder: recent advances in pharmacology and genomics eBioMedicine + +...
Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer
Pyng Leea ∙ Karim Abdelhamidb ∙ Rachel Butlerc ∙ Wendy Cooperd ∙ Misako Nagasakae ∙ Solange Petersb ∙ et al.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00105-2/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz-_nnce-hnTZlmP8VuegJpOgwgeDnLKC5ddH39XZEhtpo_ohr-4QzKAgJ-dHANhPb4cegR4xFX49J1CnTg5JqTXl6qjLcA&_hsmi=415197735&utm_content=414889854&utm_source=hs_email
Editorial
Treating alcohol use disorder: recent advances in pharmacology and genomics
eBioMedicine
https://www.thelancet.com/journals/ebiom/issue/vol126nonull/PIIS2352-3964(26)X2002-3
Editorial p309 Paediatric TB: celebrating the people behind the progress The Lancet Child & Adolescent Health +++ +...
Oral rehydration for severe malnutrition in children with moderate and severe dehydration (GASTROSAM): a phase 2, open-label, superiority randomised controlled trial
Prof Kathryn Maitland, MDa,g Send email to k.maitland@imperial.ac.uk ∙ Hadiza Sainna, MDb ∙ Roisin Connon, MScc ∙ San Maurice Ouattara, MDd ∙ Temmy Sunyoto, MDe ∙ Abdullahi Chara, MDb ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00371-2/fulltext?dgcid=hubspot_update_feature_updatealerts_lanchi&utm_campaign=update-lanchi&utm_medium=email&_hsenc=p2ANqtz-90wHLg0pdqjbcIWO_xvV4KbjwV3G6GzOHrl9A3TLv8itiYhMs80Fk6Z4sev8eUxz2sS4WbR5CNm3JBJTr-c9j4WOnZ9A&_hsmi=415159728&utm_content=414889423&utm_source=hs_email
Survival, kidney function, and complications in the first year of life following intrauterine shunting for first-trimester fetal megacystis (IUS1st): analysis of a prospective observational cohort
Eva C Weber, MDa,† Send email to evacweber@gmx.de ∙ Stefan Kohl, MDb,† ∙ Prof Ingo Gottschalk, MDa ∙ Florian Recker, MDa ∙ Nikolas Neumannb ∙ Ina Memetaj-Lang, MDc ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00011-8/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-_NFlwKjERTjkjySW1XYyyDabW35f9vB7RfDw6qUER92J9C5PzL0UjYeKgp6INfFrfPOTdhbMrcQJBxwLne4PO3nx9Z8g&_hsmi=415159728&utm_content=414889423&utm_source=hs_email
Controlled medicines for children's medical needs: a review of the scope, determinants, and consequences of inequitable access
Brandon Maser, MDa,b Send email to brandon.maser@mail.utoronto.ca ∙ Kate Lawler, BScc ∙ Ximena García-Quintero, MDd ∙ Prof Doralina Anghelescu, MD†,d ∙ Nahla Gafer, MDe,f ∙ Hammoda Abu-Odah, PhDg ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00374-8/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-8dFq1g1yDd2bZIaOxO6PwuULU8p-4oJqTAwGv7QhSgfvl0ndmqOVb_6JR9O62mL-eFHmOHYdgnH3EiaaBTDxc607Q2GQ&_hsmi=415159728&utm_content=414889423&utm_source=hs_email
Editorial
p309
Paediatric TB: celebrating the people behind the progress
The Lancet Child & Adolescent Health
https://www.thelancet.com/journals/lanchi/issue/vol10no5/PIIS2352-4642(26)X2003-X
Fucosylated IgG drives adipose tissue dysfunction during aging Download PDF Copy
https://www.news-medical.net/news/20260425/Fucosylated-IgG-drives-adipose-tissue-dysfunction-during-aging.aspx
A study published in Engineering has identified fucosylated immunoglobulin G (IgG) as a key mediator contributing to adipose tissue dysfunction during aging, offering insights into age-related metabolic disorders and potential therapeutic targets.
Editorial Oral health in the Americas: progress, gaps, and the path to universal coverage The Lancet Regional Health – Americas ++ +... +...
Non-specialist interpersonal psychotherapy versus fluoxetine for major depression and post-traumatic stress disorder in Kenyan public-sector primary care: a sequential, multiple-assignment, randomised trial
Susan M Meffert, MD MPHa Send email to susan.meffert@ucsf.edu ∙ Muthoni A Mathai, MBChB MMed PhDd ∙ Linnet Ongeri, MBChB MMede ∙ Thomas C Neylan, MDa ∙ Daniel Mwai, PhDf ∙ Dickens Onyango, MBChB MSch ∙ et al.
https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00012-9/fulltext?dgcid=hubspot_email_infocusalerts-psychiatry_feature&utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz--orSYAn8Q94SZFohk_fToNuWu00eyFAZ6AnzUfxJO7DAhx5ZkTO03SaEvbRUZqMTJ8MQb4KZrHvOLvDFWEdgy3yV8b9g&_hsmi=415697807&utm_content=415074375&utm_source=hs_email
Associations between state-level abortion restrictions and postpartum depression symptoms from a United States nationwide cohort
Maetal E. Haas-Kogana ∙ Andrea Pelletierb,c ∙ Amanda Koirec,d,e ∙ Primavera A. Spagnoloc,d,e ∙ Deborah Bartz
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00040-2/fulltext?dgcid=hubspot_email_infocusalerts-psychiatry_feature&utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz--Ix3hP9ghQfKtG_Aw7v-HdJlLg4SDlI7U50RBLXPrB5XZjiPMv1NH23K0oBAQ8hRttGaeNAJOKZxHknWncxdURnRR-FQ&_hsmi=415697807&utm_content=415074375&utm_source=hs_email
Editorial
Oral health in the Americas: progress, gaps, and the path to universal coverage
The Lancet Regional Health – Americas
https://www.thelancet.com/journals/lanam/issue/vol55nonull/PIIS2667-193X(25)X0014-4
Editorial
Generative AI chatbots in primary care
The Lancet Primary Care
https://www.thelancet.com/journals/lanprc/issue/vol2no3/PIIS3050-5143(26)X2003-9
sábado, 25 de abril de 2026
How Chemotherapy Causes Taste Changes and Loss of Appetite
https://www.news-medical.net/health/How-Chemotherapy-Causes-Taste-Changes-and-Loss-of-Appetite.aspx
Chemotherapy can change how food tastes and smells, which can reduce appetite, worsen nutrition, and lower quality of life during cancer treatment. This article explains how these changes occur, what patients commonly experience, and which supportive strategies may help, given the limited evidence for treatment.
Chemotherapy-induced taste alteration (CITA) is one of the most common sensory side effects of cancer treatment, yet it often receives far less attention than nausea, fatigue, or pain. By disrupting taste perception, CITA can significantly affect appetite, nutrition, quality of life, and a patient’s tolerance of ongoing therapy.
How Eating Slowly and Food Texture Influence Appetite and Weight
https://www.news-medical.net/health/How-Eating-Slowly-and-Food-Texture-Influence-Appetite-and-Weight.aspx
Food texture and chewing speed influence appetite, satiety, and energy intake through mechanisms of oral processing and gut signaling. These effects are modest but consistent, suggesting practical relevance for dietary behavior and weight management.
Food choices and eating behavior influence appetite and weight. An increasing body of evidence suggests that the texture of foods, as well as the rate of consumption, can influence our appetite. Solid and semi-solid foods may keep us full for longer than liquids. Meta-analytic evidence shows that solid foods reduce hunger compared to liquids (mean difference ≈ −4.97 mm on visual analog scales), while higher viscosity foods also modestly enhance fullness. Supporting this, studies show that individuals who consume whole, high-viscosity foods experience less hunger than those who consume juices and purees. These observations have increased scientific interest in the role of food texture and eating behavior in regulating appetite.1
Type 1 diabetes preserves fitness but alters oxygen use in teens
https://www.news-medical.net/news/20260424/Type-1-diabetes-preserves-fitness-but-alters-oxygen-use-in-teens.aspx
Even when fitness looks normal, hidden changes in oxygen use and microvascular function may already be emerging in adolescents with type 1 diabetes.
A new study published in Frontiers in Endocrinology reveals that type 1 diabetes is associated with subtle alterations in oxygen utilization and peripheral microvascular function in response to graded exercise in adolescents. However, this chronic metabolic condition does not appear to significantly affect cardiovascular function and overall exercise capacity.
Resistance is not futile The Lancet Global Health + + + +...
The incidence and antimicrobial resistance of Shigella-attributable diarrhoea in young children in low-income and middle-income countries from the multicountry Enterics for Global Health (EFGH) Shigella Surveillance Study: a prospective, facility-based hybrid surveillance study
Mohammad Tahir Yousafzai, PhDa,b,* ∙ Jennifer Cornick, PhDc,d,* ∙ Pablo Penataro Yori, MPHe,f,* ∙ M Jahangir Hossain, MBBSg,* ∙ Adama Mamby Keita, MDh,* ∙ Hannah E Atlas, MPHi,* ∙ et al.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00534-0/fulltext?dgcid=raven_jbs_etoc_feature_langlo
Impact of two decades of humanitarian and development assistance and the projected mortality consequences of current defunding to 2030: retrospective evaluation and forecasting analysis
Andrea Ferreira da Silva, PhDa,b,† ∙ Rodrigo Volmir Rezende Anderle, PhDa,† ∙ Gonzalo Barreix Sibils, MPHc,d,† ∙ Lucas de Oliveira Ferreira de Sales, PhDa ∙ Daiana Pena, MPHc ∙ Caterina Monti, MPHc,d ∙ et al.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00008-2/fulltext?dgcid=raven_jbs_etoc_feature_langlo
Resistance is not futile
The Lancet Global Health
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00238-4/fulltext?dgcid=raven_jbs_etoc_email
May 2026
Volume 14Number 5e668-e851
https://www.thelancet.com/journals/langlo/issue/vol14no5/PIIS2214-109X(26)X2003-4
The US CDC on the brink The Lancet + + +...
Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial
Carl Llor, PhDa,b,c,d,e,f Send email to cllor@health.sdu.dk ∙ Ramon Monfà, MSca,b,c,g ∙ Ana Garcia-Sangenís, MSca,b,c ∙ Alfonso Leiva, PhDh ∙ Jaime Marín-Cañada, MDi,j ∙ María Antonia Sánchez-Calavera, MDk ∙ et al.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02171-3/abstract?dgcid=raven_jbs_etoc_feature_lancet
The US CDC on the brink
The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00799-3/fulltext?dgcid=raven_jbs_etoc_email
Apr 25, 2026
Volume 407Number 10539p1573-1656
https://www.thelancet.com/journals/lancet/issue/vol407no10539/PIIS0140-6736(26)X2014-1
RARE Round-up - keeping you up-to-date
https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=cfec555e-0bf6-4813-9494-6b9538dbfd94&pnum=52
A clinical trial is never just a study—it’s a vessel for hope. But when programmes fail or are discontinued, families are often left with silence instead of answers. Drawing on her frontline experience as a nurse and now as head of patient engagement at Azafaros, Gisela Linthorst unpacks the ethical “duty of care” that remains when the science falls short.
Clinical trial finds no difference in fluid treatment options for pediatric sepsis
Clinical trial finds no difference in fluid treatment options for pediatric sepsis
NIH-supported study is largest ever to compare fluid interventions to prevent major kidney damage in children treated for septic shock.
https://www.nih.gov/news-events/news-releases/clinical-trial-finds-no-difference-fluid-treatment-options-pediatric-sepsis
A large clinical trial supported by the National Institutes of Health (NIH) compared two commonly used treatments for pediatric patients treated for septic shock and found no difference in meaningful outcomes. The trial, which enrolled over 9,000 participants across five countries, sought to answer a longstanding question about which intravenous crystalloid fluid type was the superior option for children who were in septic shock, a life-threatening condition triggered by severe infection which requires immediate medical treatment.
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institutes of Health https://www.nih.gov/
For Immediate Release: Friday, April 24, 2026
CONTACT: NIH Office of Communications, https://www.hhs.gov/request-for-comment-form/index.html?Agency=NIH
CLINICAL TRIAL FINDS NO DIFFERENCE IN FLUID TREATMENT OPTIONS FOR PEDIATRIC SEPSIS
NIH-supported study is largest ever to compare fluid interventions to prevent major kidney damage in children treated for septic shock
A large clinical trial supported by the National Institutes of Health (NIH) compared two commonly used treatments for pediatric patients treated for septic shock and found no difference in meaningful outcomes. The trial, which enrolled over 9,000 participants across five countries, sought to answer a longstanding question about which intravenous crystalloid fluid type was the superior option for children who were in septic shock, a life-threatening condition triggered by severe infection which requires immediate medical treatment.
“For decades, pediatricians have debated which is the best intravenous resuscitation treatment for children with severe infections who have suspected septic shock,” said Rohan Hazra, M.D., acting director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, which funded the study. “This largest-ever clinical trial for children treated for septic shock has immediate clinical application and allows physicians caring for these vulnerable patients to know they can confidently choose either intervention as a standard of care.”
For the study, scientists sought to compare balanced crystalloid fluid, an IV solution designed to closely mimic the electrolyte composition of human plasma, to a 0.9% saline IV solution. They assigned over 4,200 participants between the ages of 2 months and 17 years into each arm of the trial and found no significant differences between the groups for incidences of death, persistent kidney disfunction, or new renal-replacement therapy (a type of dialysis treatment to temporarily replace kidney function).
Participants in both groups received their assigned IV fluid type for 24-48 hours and achieved a median of 23 hospital-free days during the 28 days following enrollment. Children receiving the 0.9% saline solution had significantly higher incidences of abnormally high levels of chloride and sodium in their blood, while those receiving the balanced fluid had slightly higher incidence of abnormally high lactate in their blood. These were expected biochemical differences caused by the different fluid types, but, notably, this study found that these fluid-induced differences in blood profiles did not translate into meaningful differences in patient outcomes. There were also no other differences in safety outcomes between the treatments.
Researchers acknowledge that while their trial’s large sample size allowed them to identify small differences in patient outcomes, there were still some limitations for broader application of treatments. Because the study targeted children with community-acquired sepsis who presented to an emergency department in high-resource locations, the authors are uncertain if these results can be generalized to low-resource settings or when a patient has hospital-acquired sepsis. Additionally, because treatment was initiated when septic shock was suspected using immediate clinical observations rather than waiting for abnormal laboratory results, which are often not available when symptoms appear, the authors cannot exclude the possibility that a specific fluid type could be preferred among the sickest subset of children or those who require treatment with very high fluid volumes. Despite these limitations, these results now confirm that emergency physicians can be reassured that either balanced fluid or 0.9% saline are safe and effective for children treated for septic shock.
This research was supported by NIH grants R01HD101528 and P50DK114786 and led by the Pediatric Emergency Care Applied Research Network (PECARN), a network for research in pediatric emergency medicine funded through Emergency Medical Services for Children (EMSC) program of the Health Resources and Services Administration (HRSA) in collaboration with institutions in Canada, Australia, New Zealand, and Costa Rica.
About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD leads research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. For more information, visit https://www.nichd.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
---
REFERENCE: Balamuth F, Weiss SL, Long E, et al. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock. N Engl J Med. DOI: 10.1056/NEJMoa2601969.
###
This NIH News Release is available online at:
https://www.nih.gov/news-events/news-releases/clinical-trial-finds-no-difference-fluid-treatment-options-pediatric-sepsis
Neurofibromatosis type 1 Roots, resilience and the reality of NF1 25 April 2026 ++++
https://rarerevolutionmagazine.com/digitalspotlight/roots-resilience-and-the-reality-of-nf1/
We are delighted to launch our newest Digital spotlight all about neurofibromatosis type 1(NF1). Huge thank you to our sponsors Childhood Tumour Trust who celebrate their 10th anniversary as a charity in 2026. Dive in to hear from Vanessa Martin, the CTT Youth Ambassadors as well as specialists Katrina Kettle and Mary Thomas.
For ten years, Childhood Tumour Trust (CTT) have been a lifeline. Founded by Vanessa Martin, after her daughter Nicole discovered the transformative power of “camp”, CTT tackles the hidden realities of neurofibromatosis type 1 (NF1). Through camps, their youth ambassador programme, regional support and relentless advocacy, CTT offers families a soft landing, a powerful community and a voice that won’t be ignored
Written by Nicola Miller, RARE Revolution
Interview with Vanessa Martin, founder and CEO, Childhood Tumour Trust
Neurofibromatosis type 1
The journey of care in NF1: referral, review, and ‘gold’ standards of care
25 April 2026
https://rarerevolutionmagazine.com/digitalspotlight/the-journey-of-care-in-nf1-referral-review-and-gold-standards-of-care/
Neurofibromatosis type 1 (NF1) sits in a curious space: common enough to be regularly encountered but complex enough that many clinicians feel out of their depth. Mary Thomas, lead advanced nurse practitioner (adults), and Katrina Kettle, paediatric deputy clinical nurse specialist, are working to shape what “gold standard” NF1 care should look like—across a lifetime. From first referral to complex tumour management, their vision centres on three pillars: timely recognition, structured surveillance and empowered individuals.
The “window of opportunity”: why early diagnosis in NF1 matters
25 April 2026
https://rarerevolutionmagazine.com/digitalspotlight/the-window-of-opportunity-why-early-diagnosis-in-nf1-matters/
Early diagnosis in neurofibromatosis type 1 (NF1) can’t predict every outcome, but it can provide a roadmap. From childhood surveillance for optic pathway gliomas and scoliosis, to timely SEN support and informed family-planning decisions, a formal “label” opens doors to protections that guesswork never can. Specialist nurses Katrina Kettle and Mary Thomas share how early recognition, clear guidance and peer connection turn fear of NF1 into informed, proactive care for the whole family.
Neurofibromatosis type 1
NF1 healthcare transition – overview and infographic
25 April 2026
https://rarerevolutionmagazine.com/digitalspotlight/nf1-healthcare-transition-overview-and-infographic/
Malaria Treatment & Management ++
Malaria Treatment & Management
Updated: Sep 03, 2024
Author: William N Bennett, V, MD, FACP; Chief Editor: Michael Stuart Bronze, MD
https://emedicine.medscape.com/article/221134-treatment?ecd=mkm_ret_260425_mscpmrk-OUS_2AngDiscussions_etid8281613&uac=148436CN&impID=8281613
Funding Cuts Challenge Malaria Vaccination Initiatives
Heidi Splete
https://www.medscape.com/viewarticle/funding-cuts-challenge-malaria-vaccination-initiatives-2026a1000bra?ecd=mkm_ret_260425_mscpmrk-OUS_2AngDiscussions_etid8281613&uac=148436CN&impID=8281613
April 15, 2026
Editorial p325 Closing Europe's stroke prevention and care gaps by 2030 The Lancet Neurology + +...
Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study
Niklas Mattsson-Carlgren, MDa,b,c Send email to niklas.mattsson-carlgren@med.lu.se ∙ Sebastian Palmqvist, MDa,b ∙ Kanta Horie, PhDd,e,j ∙ Nicolas Barthélemy, PhDd,e ∙ Gemma Salvadó, PhDa,k ∙ Alexa Pichet Binette, PhDa,l,m ∙ et al.
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00029-3/fulltext?dgcid=hubspot_email_infocusalerts-neurology_feature&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz-_HuxgRbiVYvRKsi6KIgXYLfakMGU2GkolyHnKkecxl29OwqLafkzRcRDZ_JN2ygs1k4FMClUc5q8nmFLJearSgmBuriQ&_hsmi=415600531&utm_content=415074509&utm_source=hs_email
Editorial
p325
Closing Europe's stroke prevention and care gaps by 2030
The Lancet Neurology
https://www.thelancet.com/journals/laneur/issue/vol25no4/PIIS1474-4422(26)X2002-6
Editorial Barriers to accessing cataract surgery The Lancet Healthy Longevity + +...
The effects of daily low-dose aspirin on white matter hyperintensity lesions and retinal vascular calibre in healthy older adults: the ENVIS-ion exploratory neuroimaging substudy of the ASPREE randomised clinical trial
Walter P Abhayaratna, MBBS PhDa,b Send email to walter.p.abhayaratna@act.gov.au ∙ Prof Christopher M Reid, PhDb,d ∙ Katherine L Webb, MAb ∙ Prof Rory Wolfe, PhDb ∙ Ruth E Trevaks, PhDb ∙ Liubov Robman, MBBS PhDb,e ∙ et al.
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00134-5/fulltext?dgcid=hubspot_email_infocusalerts-neurology_feature&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz-_P3P7QoN4l0jUUt24XjqeblMtdTiqbx7SgSezWtBpQxa4lYiUvbEpsehJVEy4q8BmtJ2kUZNQzba9bkj7JzshfHhEJzw&_hsmi=415600531&utm_content=415074509&utm_source=hs_email
Editorial
Barriers to accessing cataract surgery
The Lancet Healthy Longevity
https://www.thelancet.com/journals/lanhl/issue/vol7no2/PIIS2666-7568(26)X2002-5
Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV
Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations. The guidelines were updated to comply with Executive Orders.
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new
What’s New in the Guidelines
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new
Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations. The guidelines were updated to comply with Executive Orders.
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
Mycobacterium avium Complex Disease
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/mycobacterium-avium-complex
Varicella-Zoster Virus Disease
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/varicella-zoster-virus
Mental health on TikTok: themes and content creators behind the hashtag #saudemental in Brazil Letícia Piantino Marques [1] , Ana Laura Vilamaior Taboga [1] , Clarissa Mendonça Corradi-Webster* [1]
https://www.academia.edu/2997-9196/3/2/10.20935/MHealthWellB8264
Introduction: Social media platforms have become important spaces where mental health information circulates and where users interpret and share experiences related to psychological well-being. This study aimed to identify the main themes circulating in TikTok videos tagged with the Brazilian Portuguese hashtag #saudemental (#mentalhealth) and to characterize the professional profiles of their creators.
Materials and methods: This exploratory cross-sectional study employed inductive qualitative content analysis of the 100 most-liked videos using the hashtag, totaling more than 54 million likes. Public metadata, full video transcriptions, and self-declared professional information were analyzed. Coding was based on units of meaning, which were grouped into thematic categories. Descriptive statistics were used to contextualize engagement metrics.
Results: Ten thematic categories emerged, with content centered on psychiatric diagnoses and symptoms representing the largest proportion of the sample (33 out of 100 videos). The analyzed videos accumulated more than 494 million views. Within the diagnosis-focused category, 55% were informative videos. Among the 100 creators, 46 did not disclose any professional or academic background, 26 identified themselves as psychologists, and only 10 of these provided a professional registration number. Among the ten most-followed creators, none identified as psychologists or psychiatrists.
Conclusions: The findings indicate a strong circulation of psychopathological discourse within short-form video environments, reinforcing the prominence of diagnostic language in everyday interpretations of emotional experience. By examining the Brazilian context, this study contributes to international discussions on the reinforcement of distress framed through medical narratives in digital spaces and highlights the need for strengthened digital and health literacy initiatives on algorithmically curated platforms.
https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav
Suscribirse a:
Entradas (Atom)
.png)
